Skip to main content

Table 5 Multivariate logistic regression analyses of multiple infections and HPV vaccine subgroups

From: Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination

Characteristics N of CIN2+ (%) OR (95%CI) p-value
Vaccine subgroupa
 16/18 295 (67.0) 4.6 (3.2-6.7) <0.001
 6/11b 3 (0.7) NA NA
 31/33/45/52/58 108 (24.5) 2.5 (1.7-3.7) <0.001
 16/18/31/33/45/52/58 403 (91.3) 3.7 (2.6-5.3) <0.001
 35/39/51/56/59/66/68 34 (7.7) 1  
Age (Y) 440 (100.0) 0.99 (0.98-1.0) 0.086
Screening sites
 County A 135 (30.7) 0.6 (0.5-0.8) < 0.001
 County B 153 (34.8) 0.9 (0.7-1.1) 0.197
 County C 152 (34.5) 1  
HPV infection pattern
 lrHPV only 3 (0.7) NA NA
 hrHPV only 424 (96.4) 1.0 (0.5-2.0) 0.94
 hrHPV+ lrHPV 13 (3.0) 1  
No. HPV typesc
 1 311 (70.7) 1 1
 2 99 (22.5) 1.1 (0.8-1.4) 0.602
  ≥ 3 30 (6.8) 0.9 (0.6-1.4) 0.568
  ≥ 2 (Multiple infection) 129 (29.3) 1.0 (0.8-1.3) 0.838
No. types, non-HPV16c
 1 117 (26.6) 1  
 2 37 (8.4) 1.1 (0.8-1.7) 0.543
  ≥ 3 7 (1.6) 0.5 (0.2-1.2) 0.128
  1. Abbreviations: OR odds ratio, CI confidence interval, NA not available, CIN2+ cervical intraepithelial neoplasia 2 or worse
  2. aThe analysis was adjusted for age, screening sites
  3. bHPV6/11 indicates only HPV6/11 infection, but excludes those coinfected with HPV6/11 and high-risk genotypes
  4. cThe analysis was adjusted for age, screening sites and HPV infection pattern